Awakn Life Sciences will be carrying out the first-ever study investigating the use of ketamine treatment for gambling addiction, using psychedelic-assisted psychotherapy.
Mydecine Innovations Group has signed a five-year psychedelic research agreement with Johns Hopkins University School of Medicine.
Psycheceutical has been granted exclusive license of two major patents that will psychedelic compounds to be administered without any side effects.
Diamond Therapeutics has received approval from Health Canada to carry out a clinical trial for the treatment of mental health conditions with low-dose psilocybin.
A systematic review of medical research has shown that ketamine and esketamine show no adverse cognitive effects in treatment-resistant depression.
Salvinorin A, derived from the plant Salvia divinorum, is to be researched as a treatment for mental health conditions.
A new review has suggested mixing classic psychedelics with lithium could pose a heightened risk of seizures.
Wesana Health is to undertake a functional animal study to determine the effect of psilocybin treatment on Traumatic Brain Injury (TBI), and anxiety and depression.
A team of researchers has identified novel mechanistic insights on how ketamine exerts an anti-depression effect, raising the hope of finding new treatment options for the...
UK scientists are to research the potential of psilocybin to boost the effects of talking therapies for people with an end-of-life diagnosis.
